AI-assisted international press reviewPress review

Kisqali® Shows Significant Overall Survival Improvement in HR+/HER2- Breast Cancer

The six-year analysis results from the NATALEE trial indicate that Kisqali® (ribociclib) combined with endocrine therapy reduces the risk of death by nearly 20% in patients with high-risk HR+/HER2- breast cancer. These findings reinforce Kisqali's role as a standard treatment, with benefits continuing to increase over time and no new safety issues reported. These results will be presented at the ESMO 2026 congress.

Source: Novartis, published under the title "Kisqali® shows clinically meaningful overall survival in bro..." - 23 October 2026

Johnson & Johnson Unveils Promising Advances in Oncology with JNJ-6143

At the ESMO 2026 congress, Johnson & Johnson will present significant clinical results on JNJ-6143, an innovative treatment for prostate cancer, as well as data on other solid tumors. These results underscore the company's commitment to transforming cancer treatment through innovative biological approaches and addressing unmet medical needs.

Source: J&j - 23 October 2026

Finerenone Shows Promising Results for Kidney Protection Without Diabetes

New analyses from the FIND-CKD study indicate that finerenone significantly reduces proteinuria and slows the decline of kidney function in patients with chronic kidney disease without diabetes, particularly those suffering from focal segmental glomerulosclerosis and IgA nephropathy. These findings highlight the importance of finerenone as a therapeutic option in this clinical context.

Source: Bayer, published under the title "Finerenone showed consistent effects in reduction of UPCR, U..." - 23 October 2026

Johnson & Johnson Unveils Advances in Electrophysiology at APHRS 2026

At the Asia Pacific Heart Rhythm Society 2026, Johnson & Johnson presented significant results from the VARIPURE and Omny-IRE studies, demonstrating the efficacy and safety of its new pulsed field ablation technologies for treating atrial fibrillation, with high success rates and notable improvements in patients' quality of life.

Source: J&j - 22 October 2026

AskBio Unveils Advances in Gene Therapies at ESGCT Congress

At the 33rd Annual Congress of the European Society of Gene and Cell Therapy, AskBio showcases its innovations in the production of adeno-associated viruses (AAV), aimed at enhancing the production of gene therapies for severe diseases. These presentations highlight the company's commitment to making these treatments more accessible and effective for millions of patients worldwide.

Source: Bayer, published under the title "AskBio Announces 5 Presentations at the European Society of ..." - 22 October 2026

Johnson & Johnson Unveils Advances in Rheumatological Disease Treatments

At ACR 2026, Johnson & Johnson presented key data on its innovative treatments, including nipocalimab for Sjögren's disease, demonstrating significant improvements in patient symptoms and quality of life. Results on TREMFYA and ICOTYDE also highlight the company's commitment to addressing unmet needs in autoimmune diseases, reinforcing its role as a leader in rheumatology.

Source: J&j - 22 October 2026

Ultomiris Receives First Approval to Reduce Proteinuria in IgAN Patients

Ultomiris, the first C5 complement inhibitor, has received accelerated approval in the United States to reduce proteinuria in adults with primary immunoglobulin A nephropathy, based on promising results from the I CAN clinical trial. This approval marks a significant advancement in the treatment of this rare kidney disease, affecting over 200,000 people in the United States, and underscores the importance of innovation in the field of renal health.

Source: Astrazeneca, published under the title "Ultomiris received accelerated approval in the US as first a..." - 22 October 2026

Novartis Secures Approval for Cosentyx® to Treat Polymyalgia Rheumatica in Europe

The European Commission has approved Cosentyx® (secukinumab) for the treatment of polymyalgia rheumatica in adults, marking a significant advancement in managing this inflammatory disease. With promising results from the REPLENISH trial, Cosentyx becomes the first interleukin-17A inhibitor approved for this condition, providing an alternative to traditional steroid-based treatments, which are often associated with undesirable side effects.

Source: Novartis, published under the title "Novartis receives European Commission approval for Cosentyx®..." - 22 October 2026

Abbott Plans to Spin Off Nutrition Business into Independent Company

This strategic separation will allow Abbott and its new Nutrition company to focus on distinct growth opportunities, emphasizing innovation and value creation in their respective markets. The new Nutrition company, expected to generate approximately $8.5 billion in annual sales, will position itself as a global leader in the healthy nutrition sector, while Abbott will continue to focus on its diversified health businesses, with projected sales of $42 billion.

Source: Abbott, published under the title "Abbott Announces Its Intention To Separate Its Global Nutrit..." - 21 October 2026

Novartis Rises to 19th Place in TIME's Global Company Rankings for 2026

In the 2026 ranking by TIME and Statista, Novartis has climbed to 19th place, reflecting bold changes within the company. This leap from 114th to 19th position is attributed to improved business results, a more engaging corporate culture, and a strengthened commitment to sustainability. Over 70,000 employees are working together to tackle health challenges and transform the future of medicine while creating value for patients, employees, and society as a whole.

Source: Novartis, published under the title "Novartis ranks #19 in TIME and Statista’s World’s Best Compa..." - 21 October 2026

Abbott Reports Strong Q3 2026 Results and Optimistic Outlook

Abbott recorded a 14.5% sales growth in Q3 2026, with an adjusted diluted earnings per share of $1.42. The company expanded its portfolio with approvals for new products, including a biowearable sensor for diabetes management. Sales of medical devices and diagnostics also saw significant increases. Abbott anticipates comparable sales growth of about 6% for 2026 and declared a quarterly dividend of $0.63 per share, continuing its tradition of dividend increases for 54 consecutive years.

Source: Abbott, published under the title "Abbott Reports Third-Quarter 2026 Results And Reaffirms Full..." - 21 October 2026

Merck Partners with NVIDIA and Microsoft to Support Rare Tumor Patients

In an unprecedented collaboration, Merck, NVIDIA, Microsoft, and Dawn Health are joining forces to develop a support model for patients living with rare tumors, integrating AI technologies to provide personalized and accessible assistance. This project aims to transform the care experience by making support more responsive and continuous, particularly for dispersed patient populations with complex needs.

Source: Merck, published under the title "Merck Collaborates with NVIDIA, Microsoft and Dawn Health to..." - 21 October 2026

Tezspire Shows Promising Results in CROSSING Trial for Eosinophilic Esophagitis

Results from the CROSSING trial indicate that Tezspire, a biological treatment, significantly improves symptoms and histological remission in patients with eosinophilic esophagitis, with lasting effects observed for up to 52 weeks. These advancements could transform the treatment landscape for this rapidly growing chronic condition.

Source: Astrazeneca, published under the title "Tezspire positive results from Phase III CROSSING trial in e..." - 21 October 2026

Hibsago: A Major Breakthrough in Chronic Hepatitis B Treatment

The FDA has approved Hibsago (bepirovirsen), a revolutionary treatment for chronic hepatitis B, offering unprecedented functional cure rates. This six-month treatment, with an option for self-administration, could transform the management of millions of patients in the United States, according to phase III clinical trial results.

Source: Gsk, published under the title "Hibsago (bepirovirsen) approved in the US for the treatment ..." - 21 October 2026

Johnson & Johnson Showcases Surgical Innovation at Abu Dhabi Summit

At the Future Health Summit, Johnson & Johnson will present its MONARCH™ platform and the Polyphonic™ digital ecosystem, in collaboration with the Abu Dhabi Department of Health, to promote surgical intelligence and enhance patient outcomes through advanced technologies and connected data.

Source: J&j - 20 October 2026

Duvakitug Shows Promising Long-Term Results for Ulcerative Colitis and Crohn's Disease

At the UEG Week 2026, data from the RELIEVE UCCD study revealed that duvakitug maintained significant long-term clinical results for patients with ulcerative colitis and Crohn's disease. The results show high rates of remission and endoscopic improvement, while being well tolerated by patients. These advancements highlight the potential of duvakitug in managing inflammatory bowel diseases, with biomarkers indicating a reduction in inflammation and fibrosis.

Source: Sanofi, published under the title "Media Update: UEG Week: Sanofi and Teva’s duvakitug maintain..." - 20 October 2026

Launch of the Shockwave C2 Aero Fly IVL Catheter for More Effective Coronary Interventions

Johnson & Johnson unveils its new IVL catheter designed to enhance the effectiveness of treatments for calcified coronary lesions by reducing intervention time and addressing the growing needs of cardiac catheterization labs. With a doubled pulse frequency and reduced wait time, this device promises to transform care for patients suffering from coronary artery disease, one of the leading causes of mortality worldwide.

Source: J&j - 20 October 2026

Abbott's Cologuard Plus Receives CE Mark for Colorectal Cancer Screening in Europe

The Cologuard Plus test, designed to detect colorectal cancer and early lesions, has received CE marking, marking a significant advancement for Abbott in its rollout across Europe. With a sensitivity of 95% and specificity of 94%, this non-invasive test could transform colorectal cancer screening on the continent, where participation in screening remains insufficient. Abbott plans a phased introduction in various European markets, addressing a crucial public health need.

Source: Abbott, published under the title "Abbott's Cologuard Plus® Receives CE Mark For Colorectal Can..." - 20 October 2026

AstraZeneca and Oracle Partner to Enhance Clinical Trials with AI

AstraZeneca and Oracle Health are joining forces to transform clinical research by integrating artificial intelligence and real-world data, aiming to improve patient care pathways and accelerate recruitment for clinical trials. This partnership will focus on key areas such as oncology and cardiovascular diseases, with an initial program in Abu Dhabi to support hypertension-related care.

Source: Astrazeneca, published under the title "AstraZeneca and Oracle launch global AI collaboration to adv..." - 20 October 2026

Jemperli: First Immunotherapy Approved for Advanced Rectal Cancer in the U.S.

The approval of Jemperli is based on promising data from the AZUR-1 study, which showed that a significant proportion of patients had no signs of cancer one year after treatment. With a median follow-up of over two years, no cases of recurrence were observed, providing a new therapeutic option that could spare patients from chemotherapy, radiotherapy, and surgery.

Source: Gsk, published under the title "Jemperli (dostarlimab) approved in US as first and only immu..." - 20 October 2026